New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePalmitoyl Tetrapeptide-7 vs Dermorphin

Palmitoyl Tetrapeptide-7 vs Dermorphin

Side-by-side comparison of key properties, dosing, and research.

Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Recovery & Repair
Dermorphin
Summary
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Half-Life
Topical penetration-dependent; effects last hours to days
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
Admin Route
Topical
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Research
Typical Dose
2-5 ppm concentration in formulation
Not established for human use; research doses vary widely
Frequency
Twice daily
Not established
Key Benefits
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
Side Effects
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
Stacks With